FOLLOWUS
Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial
Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial
- 中国结合医学杂志（英文版） 2015年21卷第6期 页码：408-416
- Affiliations：
1. Cardiovascular Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences,Guangzhou,China
2. Postdoctoral Mobile Research Station, Guangzhou University of Traditional Chinese Medicine,Guangzhou,China
3. Cardiovascular Department of Ershadao Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,China
4. Cardiac Surgeon Department of University Town Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,China
5. Cardiovascular Department of Fangcun Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,China
6. Cardiovascular Department of University Town Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,China
- Author bio：
- Funds：Supported by the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (No. 2001BAI10B02) and Science and Technology Planning Project of Guangdong Province, China (No. 2012A032500017)
DOI：10.1007/s11655-015-2040-6
中图分类号：纸质出版日期：2015，
网络出版日期：2015-6-11，
Scan for full text
Xu, Dp., Wu, Hl., Lan, Th. et al. Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial., Chin. J. Integr. Med. 21, 408–416 (2015). https://doi.org/10.1007/s11655-015-2040-6
Dan-ping Xu, Huan-lin Wu, Tao-hua Lan, et al. Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2015,21(6):408-416.
Xu, Dp., Wu, Hl., Lan, Th. et al. Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial., Chin. J. Integr. Med. 21, 408–416 (2015). https://doi.org/10.1007/s11655-015-2040-6 DOI：
Dan-ping Xu, Huan-lin Wu, Tao-hua Lan, et al. Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2015,21(6):408-416. DOI： 10.1007/s11655-015-2040-6.
摘要
To evaluate the efficacy and safety of a combination therapy using Chinese medicine (CM) Shenzhu Guanxin Recipe (参术冠心方
SGR) and standard Western medicine treatment (SWMT) in patients with angina pectoris after percutaneous coronary intervention (PCI). Double-blind randomized controlled trial was used in this experimental procedure. One hundred and eighty-seven patients with coronary heart disease receiving SWMT after PCI were randomly assigned to the treatment (SGR) and control (placebo) groups. Outcome measures including angina pectoris score (APS)
CM symptom score
and Seattle Angina Questionnaire (SAQ) score were evaluated in 1
2
3 and 12 months
and the death rate
restenosis and other emergency treatments were observed. The mixed-effects models were employed for the data analysis. In the treatment group
a larger within-treatment effect size (d=1.74) was found
with a 76.7% reduction in APS from pretreatment to 12-month follow-up assessment compared with the control group (d=0.83
53.8% symptom reduction); betweentreatment (BT) effect size was d=0.66. CM symptom scores included an 18.3% reduction in the treatment group (d=0.46)
and a 16.1% decrease in the control group (d=0.31); d=0.62 for BT effect size. In regard to scores of SAQ
the BT effect size of cognition level of disease was larger in the treatment group (d=0.63)
followed by the level of body limitation of activity (d=0.62)
condition of angina pectoris attacks (d=0.55)
satisfaction level of treatments (d=0.31)
and steady state of angina pectoris (d=0.30). Two cardiovascular related deaths and one incidental death were recorded in the control and treatment groups
respectively. No significant difference in any cardiovascular event (including death toll
frequency of cardiovascular hospitalization or emergency room visits) was found between the two groups. The combination therapy of SGR and SWMT is effective and safe in patients with angina pectoris after PCI when compared with SWMT alone.
Abstract
To evaluate the efficacy and safety of a combination therapy using Chinese medicine (CM) Shenzhu Guanxin Recipe (参术冠心方
SGR) and standard Western medicine treatment (SWMT) in patients with angina pectoris after percutaneous coronary intervention (PCI). Double-blind randomized controlled trial was used in this experimental procedure. One hundred and eighty-seven patients with coronary heart disease receiving SWMT after PCI were randomly assigned to the treatment (SGR) and control (placebo) groups. Outcome measures including angina pectoris score (APS)
CM symptom score
and Seattle Angina Questionnaire (SAQ) score were evaluated in 1
2
3 and 12 months
and the death rate
restenosis and other emergency treatments were observed. The mixed-effects models were employed for the data analysis. In the treatment group
a larger within-treatment effect size (d=1.74) was found
with a 76.7% reduction in APS from pretreatment to 12-month follow-up assessment compared with the control group (d=0.83
53.8% symptom reduction); betweentreatment (BT) effect size was d=0.66. CM symptom scores included an 18.3% reduction in the treatment group (d=0.46)
and a 16.1% decrease in the control group (d=0.31); d=0.62 for BT effect size. In regard to scores of SAQ
the BT effect size of cognition level of disease was larger in the treatment group (d=0.63)
followed by the level of body limitation of activity (d=0.62)
condition of angina pectoris attacks (d=0.55)
satisfaction level of treatments (d=0.31)
and steady state of angina pectoris (d=0.30). Two cardiovascular related deaths and one incidental death were recorded in the control and treatment groups
respectively. No significant difference in any cardiovascular event (including death toll
frequency of cardiovascular hospitalization or emergency room visits) was found between the two groups. The combination therapy of SGR and SWMT is effective and safe in patients with angina pectoris after PCI when compared with SWMT alone.
关键词
Shenzhu Guanxin Recipeangina pectorisPercutaneous Coronary Interventioncoronary heart diseaserandomized controlled trialChinese Medicine
Keywords
Shenzhu Guanxin Recipeangina pectorisPercutaneous Coronary Interventioncoronary heart diseaserandomized controlled trialChinese Medicine
references
Zhang HC, Guo JH. Epidemiology and primary prevention of coronary heart disease. Chin J Pract Intern Med (Chin) 2002;22:499–450.
Horlitz M, Siguartu U, Niebauer J. Fighting restenosis after coronary angioplasty contemporary and future treatment to options. Int J Cardiol 2002;83:199–205.
Ji LN, Tong XL, Wang HY, Tian HM, Zhou HM, Zhang LL, et al. Efficacy and safety of traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One 2013;8:e56703.
Volpi E, Giusti L, Ciregia F, Da Valle Y, Giannaccini G, Berti S, et al. Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention. Clin Biochem 2012;45:758–765.
Han YL, Li Yi, Wang SL, Jing QM, Wang ZL, Wang DM, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733–739.
Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, et al. A randomized, double-blind, activecontrolled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 2012;5:336–346.
Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Schöller R. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012;4:305–312.
Park JB, Koo BK, Choi WG, Kim SY, Park J, Kwan J, et al. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, openlabel, phase IV, noninferiority trial. Clin Ther 2013;35:28–37.
Song PS, Hahn JY, Song YB, Choi JH, Choi SH, Kang GH. Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. Yonsei Med J 2012;53:906–914.
Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol 2011;57:771–778.
Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107–1115.
Wu HL, Wang X, Li XM, Luo WJ, Deng TT. Trial study on DENG Tie-tao's coronary heart disease capsules in improving patients' quality of life. Chin J Integr Med 2005;11:173–178.
Ren Y, Zhang MZ, Chen KJ, You SJ, Li JJ, Guo LH, et al. Clinical and epidemiological investigation of TCM syndromes of patients with coronary heart disease in China. Evid Based Complement Alternat Med 2012;2012:714517.
Xu DP, Wang X, Sheng XG, Lin Y, Li S, Zheng CY, et al. Double-blind, randomized, controlled clinical trail of Shenzhu Guanxin Prescription for treatment of stable angina due to cronary heart disease. J Guangzhou Univ Tradit Chin Med (Chin) 2014;31:173–182.
Xu DP, Wu HL. Effect of Shenzhu Guanxin Granula on coronary circulation in rats with myocardial infarction. Chin J Pathophysiol (Chin) 2014;30:438–443.
Deedwania PC, Carbajal EV. Getting with the ACC/AHA guidelines for the treatment of chronic angina as a disease state. Rev Cardiovasc Med 2009;10:11–20.
Long C. Interpretation of guideline for clinical study on angina pectoris of CHD treated with traditional Chinese medicines and natural medicines. China Licens Pharm (Chin) 2012;9:3–6.
Ertl V, Pfeiffer A, Schauer E, Elbert T, Neuner F. Community-implemented trauma therapy for former child soldiers in Northern Uganda: a randomized controlled trial. JAMA 2011;306:503–512.
White J, American Heart Association. AHA statement highlights gender differences in PCI: part II. J Interv Cardiol 2005;18:355–356.
Wu HL, Ruan XM, Luo WJ, Ou AH, Yang XB, Chen KJ, et al. Cluster analysis on TCM syndromes in 319 coronary artery disease patients for establishment of syndrome diagnostic figure. Chin J Integr Tradit West Med (Chin) 2007;27:616–618.
Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994;74:1240–1244.
Jiang W, Run XM, Lin Y, Hu JX, Wu HL, Chen QX, et al. Clinical study on patients treated by the method for regulating Pi (Spleen) and protecting Xin (Heart) after offpump coronary artery bypass grafting operation. Shandong J Tradit Chin Med (Chin) 2005;26:339–340.
Run XM, Jiang W, Lin Y, Hu JX, Wu HL, Chen QX, et al. The effect of the method for regulating Pi (Spleen) and protecting Xin (Heart) on the clinical therapeutic effect and quality of life of patients after coronary artery bypass grafting operation. Chin J Integr Tradit West Med (Chin) 2006;26:28–29.
Wu HL, Xu DP, Luo WJ. Retrospective cohort study on the improvement of the prognosis of patients after coronary artery bypass grafting operation treated by the method for regulating Pi (Spleen) and protecting Xin (Heart). Jilin J Tradit Chin Med (Chin) 2009;29:27–29.
Wu GP, Wu XX. The clinical experiences on treating coronary heart disease of DENG Tie-tao. J Emerg Tradit Chin Med (Chin) 2009;18:1112–1113.
Xu DP, Wang X, Li XQ, Luo WJ, Wu HL. The effect of DENG Tie-tao scheme on patients with coronary heart disease. Chin J Gerontol (Chin) 2014;34:1167–1168.
Wang L, Zhang MZ, Guo LH, Qi JY, Luo HM, He HK. Clinical pathways based on integrative medicine in Chinese hospitals improve treatment outcomes for patients with acute myocardial infarction: a multicentre, nonrandomized historically controlled trial. Evid Based Complement Alternat Med 2012;2012:821641.
Cui XY, Wu Y, Nong YB. Effect of Liangxue Shengji Recipe on incidence of post-percutaneous coronary intervention restenosis and adverse cardiovascular events. Chin J Integr Tradit West Med (Chin) 2010;30:30–32.
Li AH, Gong KZ, Yan JF. Effect of Shuxuetong in preventing restenosis after intracoronary stenting. Chin J Integr Tradit West Med (Chin) 2004;24:879–881.
Shang QH, Xu H, Lu XY, Wen C, Shi DZ, Chen KJ. A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. Chin J Integr Med 2011;17:669–674.
Yu B, Chen KJ, Mao JM, Guo JX, Lu SZ. Clinical study on effect of concentrated Xuefu Zhuyu Pill on restenosis of 43 cases coronary heart disease after intracoronary stenting. Chin J Integr Tradit West Med (Chin) 1998;18:585–589.
Guo XY, Liu J, Liu J, Li HJ, Qi Y, Qin LP. Use of traditional Chinese medicine in Chinese patients with coronary heart disease. Biomed Environ Sci 2013;26:303–310.
Zheng GH, Liu JP, Wang NS, Chen HY, Chun JF. Systematic review of Chinese herbal medicines for preventing in-stent coronary restenosis after percutaneous coronary intervention. Evid Based Complement Alternat Med 2012;2012:253409.
0
浏览量
221
Downloads
3
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
